The impact of a pharmacist on post-take ward round prescribing and medication appropriateness

被引:0
作者
B. Bullock
P. Donovan
C. Mitchell
J. A. Whitty
I. Coombes
机构
[1] Royal Brisbane and Women’s Hospital,Pharmacy Department
[2] University of Queensland,School of Pharmacy
[3] Gold Coast Hospital and Health Service,Medical Education Unit
[4] University of Queensland,School of Medicine
[5] Royal Brisbane and Women’s Hospital,Department Clinical Pharmacology
[6] University of East Anglia,Norwich Medical School
来源
International Journal of Clinical Pharmacy | 2019年 / 41卷
关键词
Australia; Communication; Medication safety; Prescribing; Team work; Ward round;
D O I
暂无
中图分类号
学科分类号
摘要
Background Medication communication and prescribing on the post-take ward round following patient admission to hospital can be suboptimal leading to worse patient outcomes. Objective To evaluate the impact of clinical pharmacist participation on the post-take ward round on the appropriateness of medication prescribing, medication communication, and overall patient health care outcomes. Setting Tertiary referral teaching hospital, Brisbane, Australia. Method A pre-post intervention study was undertaken that compared the addition of a senior clinical pharmacist attending the post-take ward was compared to usual wardbase pharmacist service, with no pharmacist present of the post-take ward round. We assessed the proportion of patients with an improvement in medication appropriateness from admission to discharge, using the START/STOPP checklists. Medication communication was assessed by the mean number of brief and in-depth discussions, with health care outcomes measured by comparing length of stay and 28-day readmission rates. Main outcome measures: Medication appropriateness according to the START/STOPP list, number and type of discussions with team members and length of stay and readmission rate. Results Two hundred and sixty patients were recruited (130 pre- and 130-post-intervention), across 23 and 20 post-take ward rounds, respectively. Post-intervention, there was increase in the proportion of patients who had an improvement medication appropriateness (pre-intervention 25.4%, post-intervention 36.9%; p = 0.004), the number of in-depth discussions about patients’ medication (1.9 ± 1.7 per patient pre-intervention, 2.7 ± 1.7 per patient post-, p < 0.001), and the number relating to high-risk medications (0.71 ± 1.1 per patient pre-intervention, to 1.2 ± 1.2 per patient post-, p < 0.05). Length of stay and 28-day mortality were unchanged. Conclusion Clinical pharmacist participation on the post-take ward round leads to improved medication-related communication and improved medication appropriateness but did not significantly improve health care outcomes.
引用
收藏
页码:65 / 73
页数:8
相关论文
共 71 条
  • [1] Runciman WB(2003)Adverse drug events and medication errors in Australia Int J Qual Health Care 15 i49-i59
  • [2] Roughead EE(2005)Improving medication management for patients: the effect of a pharmacist on post-admission ward rounds Qual Saf Health Care 14 207-211
  • [3] Semple SJ(1999)Pharmacist participation on physician rounds and adverse drug events in the intensive care unit J Am Med Assoc 282 267-270
  • [4] Adams RJ(2002)Pharmacist participation in medical rounds reduces medication errors Am J Health Syst Pharm 59 2089-2092
  • [5] Fertleman M(2013)Medication reconciliation during transitions of care as a patient safety strategy: a systematic review Ann Intern Med 158 397-403
  • [6] Barnett N(2013)SHPA Standards of practice for clinical pharmacy services J Pharm Pract Res 43 122-146
  • [7] Patel T(2006)Clinical pharmacists and inpatient medical care: a systematic review Arch Intern Med 166 955-964
  • [8] Leape LL(2016)Ward rounds, participants, roles and perceptions: literature review Int J Health Care Qual Assur 29 364-379
  • [9] Cullen DJ(2017)Prescribing and medication communication on the post-take ward round Intern Med J 47 454-457
  • [10] Clapp MD(2008)The impact of clinical pharmacists on drug-related problems and clinical outcomes Basic Clin Pharmacol Toxicol 102 275-280